FDAapproval65% confidence
Verified Clinical Benefit | Cancer Accelerated Approvals
Source: FDA
Why This Matters
Why this matters: provides agency context on approval that may shape timing or evidence expectations for Roche.
Regulatory Analysis
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications with postmarketing trials that have verified clinical benefit and for which traditional approval has been subsequently granted for the specific indication.
Supporting Context
- Therapeutic area
- Oncology · Solid Tumors
- Sub-indication
- General
Related signal: Phase I Study of RO7566802 in Combination with Atezolizumab for Solid Tumors